Certificate of Analysis and Data Sheet

Source:
E.Coli

Catalog No.
ENZ-272

Background:

Matrix metalloproteinase-7 (MMP-7) also known as matrilysin and PUMP (EC 3.4.24.23) cleaves a number of substrates including collagen types IV and X, elastin, fibronectin, gelatin, laminin and proteoglycans. MMP-7 is closely related to the stromelysin family members but is encoded by a different gene. MMP-7 is the smallest of all the MMPs consisting of a pro-peptide domain and a catalytic domain. It lacks the hemopexin-like domain common to other members of the MMPs. MMP-7 is secreted as a 28 kDa proenzyme and can be activated in vitro by organomercurials and trypsin and in vivo by MMP-3 to a 18 kDa active MMP-7 enzyme. Once activated, MMP-7 can activate pro-MMP-1 and pro-MMP-9 but not pro-MMP-2. MMP-7 is widely expressed having been reported in elevated levels in cycling endometrium as well as in colorectal cancers and adenomas, hepatocellular carcinomas, rectal carcinomas, and approximately 50% of gliomas.

Physical Appearance:

Sterile filtered clear solution.

Formulation:

Recombinant ProMMP-7 ,at a concentration of 1mg/ml, 25mM Tris-HCl (pH 7.5), 150mM NaCl, 5mM CaCl2, 0.01% Brij-35 and 0.02% NaN3.

Stability:

ProMatrilysin, although stable at 4C for 3 weeks, should be stored desiccated below -18 C.
Please avoid freeze-thaw cycles.

Purity:

Greater than 95.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Anion-exchange FPLC.
(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained gel.

Dimers and aggregates:

Less than 1% as determined by silver-stained SDS-PAGE gel analysis.

Biological Activity:

The specific activity was found to be 1400 IU/mg.

Unit definition:

One unit is defined as the digestion of 1 ug Azocoll/min at 37蚓.

Endotoxin:

Less than 0.1 ng/ug (IEU/ug) of Recombinant ProMMP-7 .

Usage:

Prospec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.

Latest Publications:

1. 90K/Mac-2 binding protein is expressed in prostate cancer and induces promatrilysin expression.
Prostate 2006 Feb 15;66(3):283-93
2. Pericellular activation of proMMP-7 (promatrilysin-1) through interaction with CD151.
Lab Invest 2005 Dec;85(12):1489-506
3. Pharmacological inhibition of FGF receptor signaling inhibits LNCaP prostate tumor growth, promatrilysin, and PSA expression.
Mol Carcinog 2003 Oct;38(2):70-7
4. Androgens block interleukin-1 beta-induced promatrilysin expression in prostate carcinoma cells.
Prostate 2002 Sep 15;53(1):1-8
5. Fibroblast growth factor-1 induced promatrilysin expression through the activation of extracellular-regulated kinases and STAT3.
Neoplasia 2002 Jan-Feb;4(1):60-7
6. Interleukin-1beta-induced promatrilysin expression is mediated by NFkappaB-regulated synthesis of interleukin-6 in the prostate carcinoma cell line, LNCaP.
Neoplasia 2001 Nov-Dec;3(6):509-20